| 词条 | Alpha-2 adrenergic receptor | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 释义 |
The alpha-2 (α2) adrenergic receptor (or adrenoceptor) is a G protein-coupled receptor (GPCR) associated with the Gi heterotrimeric G-protein. It consists of three highly homologous subtypes, including α2A-, α2B-, and α2C-adrenergic. Some species other than humans express a fourth α2D-adrenergic receptor as well.[1] Catecholamines like norepinephrine (noradrenaline) and epinephrine (adrenaline) signal through the α2-adrenergic receptor in the central and peripheral nervous systems. Cellular localizationThe α2A adrenergic receptor is localised in the following central nervous system (CNS) structures:[2]
Whereas the α2B adrenergic receptor is localised in the following CNS structures:[2]
and the α2C adrenergic receptor is localised in the CNS structures:[2]
EffectsThe α2-adrenergic receptor is classically located on vascular prejunctional terminals where it inhibits the release of norepinephrine (noradrenaline) in a form of negative feedback.[3] It is also located on the vascular smooth muscle cells of certain blood vessels, such as those found in skin arterioles or on veins, where it sits alongside the more plentiful α1-adrenergic receptor.[3] The α2-adrenergic receptor binds both norepinephrine released by sympathetic postganglionic fibers and epinephrine (adrenaline) released by the adrenal medulla, binding norepinephrine with slightly higher affinity.[4] It has several general functions in common with the α1-adrenergic receptor, but also has specific effects of its own. Agonists (activators) of the α2-adrenergic receptor are frequently used in veterinary anaesthesia where they effect sedation, muscle relaxation and analgesia through effects on the central nervous system (CNS).[5] GeneralCommon effects include:
IndividualIndividual actions of the α2 receptor include:
Signaling cascadeThe α subunit of an inhibitory G protein - Gi dissociates from the G protein,[15] and associates with adenylyl cyclase. This causes the inactivation of adenylyl cyclase, resulting in a decrease of cAMP produced from ATP, which leads to a decrease of intracellular cAMP. PKA is not able to be activated by cAMP, so proteins such as phosphorylase kinase cannot be phosphorylated by PKA. In particular, phosphorylase kinase is responsible for the phosphorylation and activation of glycogen phosphorylase, an enzyme necessary for glycogen breakdown. Thus in this pathway, the downstream effect of adenylyl cyclase inactivation is decreased breakdown of glycogen. The relaxation of gastrointestinal tract motility is by presynaptic inhibition,[16] where transmitters inhibit further release by homotropic effects. Ligands
AgonistsNorepinephrine has higher affinity for the α2 receptor than has epinephrine, and therefore relates less to the latter's functions.[16] Nonselective α2 agonists include the antihypertensive drug clonidine,[16] which can be used to lower blood pressure and to reduce hot flashes associated with menopause. Clonidine has also been successfully used in indications that exceed what would be expected from a simple blood-pressure lowering drug: it has recently shown positive results in children with ADHD who suffer from tics resulting from the treatment with a CNS stimulant drug, such as Adderall XR or methylphenidate;[26] clonidine also helps alleviate symptoms of opioid withdrawal.[27] The hypotensive effect of clonidine was initially attributed through its agonist action on presynaptic α2 receptors, which act as a down-regulator on the amount of norepinephrine released in the synaptic cleft, an example of autoreceptor. However, it is now known that clonidine binds to imidazoline receptors with a much greater affinity than α2 receptors, which would account for its applications outside the field of hypertension alone. Imidazoline receptors occur in the nucleus tractus solitarii and also the centrolateral medulla. Clonidine is now thought to decrease blood pressure via this central mechanism. Other nonselective agonists include dexmedetomidine, lofexidine (another antihypertensive), TDIQ (partial agonist), tizanidine (in spasms, cramping) and xylazine. Xylazine has veterinary use. In the European Union, dexmedetomidine received a marketing authorization from the European Medicines Agency (EMA) on August 10, 2012 under the brand name of Dexdor.[28] It is indicated for sedation in the ICU for patients needing mechanical ventilation. In non-human species this is an immobilizing and anesthetic drug, presumptively also mediated by α2 adrenergic receptors because it is reversed by yohimbine, an α2 antagonist. α2A selective agonists include guanfacine (an antihypertensive) and Brimonidine (UK 14,304). (R)-3-nitrobiphenyline is an α2C selective agonist. AntagonistsNonselective α blockers include, A-80426, atipamezole, phenoxybenzamine, efaroxan, idazoxan*[16](experimental),[29] and SB-269,970. Yohimbine*[16] is a relatively selective alpha-2 blocker that has been investigated as a treatment for erectile dysfunction. Tetracyclic antidepressants mirtazapine and mianserin are also potent α antagonists with mirtazapine being more selective for α2 subtype (~30-fold selective over α1) than mianserin (~17-fold). α2A selective blockers include BRL-44408 and RX-821,002. α2B selective blockers include ARC-239 and imiloxan. α2C selective blockers include JP-1302 and spiroxatrine, the latter also being a serotonin 5-HT1A antagonist. See also
References1. ^{{cite journal |vauthors=Ruuskanen JO, Xhaard H, Marjamäki A, Salaneck E, Salminen T, Yan YL, Postlethwait JH, Johnson MS, Larhammar D, Scheinin M |title=Identification of duplicated fourth alpha2-adrenergic receptor subtype by cloning and mapping of five receptor genes in zebrafish |journal=Molecular Biology and Evolution |volume=21 |issue=1 |pages=14–28 |date=January 2004 |pmid=12949138 |doi=10.1093/molbev/msg224 |url=}} 2. ^1 2 {{cite journal|author1=Saunders, C |author2=Limbird, LE |journal=Pharmacology & Therapeutics|title=Localization and trafficking of alpha2-adrenergic receptor subtypes in cells and tissues|date=November 1999|volume=84|issue=2|pages=193–205|doi=10.1016/S0163-7258(99)00032-7|pmid=10596906}} 3. ^1 2 Cardiovascular Physiology, 3rd Edition, Arnold Publishers, Levick, J.R., Chapter 14.1, Sympathetic vasoconstrictor nerves 4. ^{{cite book|last=Boron|first=Walter F.|title=Medical Physiology: A Cellular and Molecular Approach|year=2012|page=360}} 5. ^1 2 {{cite journal|last=Khan|first=ZP|author2=Ferguson, CN|author3= Jones, RM|title=alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role.|journal=Anaesthesia|date=February 1999|volume=54|issue=2|pages=146–65|pmid=10215710|doi=10.1046/j.1365-2044.1999.00659.x}} 6. ^Goodman Gilman, Alfred. Goodman & Gilman's The Pharmacological Basis of Therapeutics. Tenth Edition. McGraw-Hill (2001): Page 140. 7. ^{{cite journal | vauthors = Woodman OL, Vatner SF | title = Coronary vasoconstriction mediated by α1- and α2-adrenoceptors in conscious dogs | journal = Am. J. Physiol. | volume = 253 | issue = 2 Pt 2 | pages = H388–93 | year = 1987 | pmid = 2887122 | doi = 10.1152/ajpheart.1987.253.2.H388 | issn = | df = }} 8. ^{{Cite journal| doi = 10.1161/01.CIR.0000023896.70583.9F| last1 = Sun | first1 = D.| last2 = Huang | first2 = A.| last3 = Mital | first3 = S.| last4 = Kichuk | first4 = M. R.| last5 = Marboe | first5 = C. C.| last6 = Addonizio | first6 = L. J.| last7 = Michler | first7 = R. E.| last8 = Koller | first8 = A.| last9 = Hintze | first9 = T. H.| last10 = Kaley | first10 = G.| title = Norepinephrine elicits beta2-receptor-mediated dilation of isolated human coronary arterioles| journal = Circulation| volume = 106| issue = 5| pages = 550–555| year = 2002| pmid = 12147535}} 9. ^1 Basic & Clinical Pharmacology, 11th Edition, McGrawHill LANGE, Katzung Betram G.; Chapter 9. Adrenoceptor Agonists & Sympathomimetic Drugs 10. ^{{cite journal | author = Elliott J | title = Alpha-adrenoceptors in equine digital veins: evidence for the presence of both α1 and α2-receptors mediating vasoconstriction | journal = J. Vet. Pharmacol. Ther. | volume = 20 | issue = 4 | pages = 308–17 | year = 1997 | pmid = 9280371 | doi = 10.1046/j.1365-2885.1997.00078.x }} 11. ^{{cite journal |vauthors=Sagrada A, Fargeas MJ, Bueno L | title = Involvement of α1 and α2 adrenoceptors in the postlaparotomy intestinal motor disturbances in the rat | journal = Gut | volume = 28 | issue = 8 | pages = 955–9 | year = 1987 | pmid = 2889649 | doi = 10.1136/gut.28.8.955 | pmc = 1433140 }} 12. ^1 {{cite web|title=Alpha-2 Agonists in the Treatment of ADHD|author=Arnsten, AFT|work=Medscape Psychiatry|publisher=WebMD|date=26 July 2007|accessdate=13 November 2013|url=http://www.medscape.org/viewarticle/560074}} 13. ^{{cite journal |vauthors=Wright EE, Simpson ER | title = Inhibition of the lipolytic action of beta-adrenergic agonists in human adipocytes by alpha-adrenergic agonists | journal = J. Lipid Res. | volume = 22 | issue = 8 | pages = 1265–70 | year = 1981 | pmid = 6119348 | doi = | issn = | url = http://www.jlr.org/cgi/content/abstract/22/8/1265}} 14. ^1 {{cite book |author1=Fitzpatrick, David |author2=Purves, Dale |author3=Augustine, George | title = Neuroscience | publisher = Sinauer | location = Sunderland, Mass | year = 2004 | edition = Third | chapter = Table 20:2 | pages = | isbn = 978-0-87893-725-7 | oclc = | doi = }} 15. ^{{Cite journal |author1=Kou Qin |author2=Pooja R. Sethi |author3=Nevin A. Lambert |date=August 2008 | title = Abundance and stability of complexes containing inactive G protein-coupled receptors and G proteins| journal = The FASEB Journal| volume = 22 | issue = 8 | pages = 2920–2927| doi=10.1096/fj.08-105775| pmid=18434433| url = http://www.fasebj.org/content/22/8/2920.long | pmc=2493464}} 16. ^1 2 3 4 5 6 {{cite book |author=Rang, H. P. |title=Pharmacology |publisher=Churchill Livingstone |location=Edinburgh |year=2003 |pages= |isbn=978-0-443-07145-4 |oclc= |doi=}} Page 163 17. ^{{cite web | title=Methamphetamine {{ndash}} Targets | url=http://www.drugbank.ca/drugs/DB01577#targets | work=DrugBank | publisher= University of Alberta | accessdate=31 December 2013 | date=8 February 2013}} 18. ^1 {{Cite journal| last1 = Haenisch | first1 = B.| last2 = Walstab | first2 = J.| last3 = Herberhold | first3 = S.| last4 = Bootz | first4 = F.| last5 = Tschaikin | first5 = M.| last6 = Ramseger | first6 = R.| last7 = Bönisch | first7 = H.| title = Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline| journal = Fundamental & Clinical Pharmacology| volume = 24| issue = 6| pages = 729–739| year = 2009| pmid = 20030735| doi = 10.1111/j.1472-8206.2009.00805.x}} 19. ^{{cite journal|last=Young|first=R|author2=CNS Drug Rev. (2007)|title=TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo [4,5-g]isoquinoline): discovery, pharmacological effects, and therapeutic potential|journal=CNS Drug Reviews|pmid=18078426|doi=10.1111/j.1527-3458.2007.00022.x|volume=13|issue=4|year=2007|pages=405–22|display-authors=etal}} 20. ^{{cite journal |vauthors=Millan MJ, Cussac D, Milligan G | title = Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 297 | issue = 3 | pages = 876–87 |date=June 2001 | pmid = 11356907 | doi = | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=11356907|display-authors=etal}} 21. ^{{cite journal |vauthors=Gobert A, Di Cara B, Cistarelli L, Millan MJ | title = Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 305 | issue = 1 | pages = 338–46 |date=April 2003 | pmid = 12649387 | doi = 10.1124/jpet.102.046383 }} 22. ^{{cite web|title=PDSP Ki Database |work=Psychoactive Drug Screening Program (PDSP) |author1=Roth, BL |author2=Driscol, J |url=http://pdsp.med.unc.edu/pdsp.php |publisher=University of North Carolina at Chapel Hill and the United States National Institute of Mental Health |accessdate=27 November 2013 |date=12 January 2011 |deadurl=yes |archiveurl=https://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php |archivedate=8 November 2013 |df= }} 23. ^{{cite web|title=Medscape Multispecialty {{ndash}} Home page|publisher=WebMD|accessdate=27 November 2013|url=http://reference.medscape.com/medscapetoday}}{{full|date=December 2015}} 24. ^{{cite web|title=Therapeutic Goods Administration {{ndash}} Home page|publisher=Department of Health (Australia)|accessdate=27 November 2013|url=https://www.ebs.tga.gov.au/}}{{full|date=December 2015}} 25. ^{{cite web|title=Daily Med {{ndash}} Home page|url=http://dailymed.nlm.nih.gov/dailymed/index.cfm|publisher=U.S. National Library of Medicine|accessdate=27 November 2013}}{{full|date=December 2015}} 26. ^National Institute of Neurological Disorders and Stroke (2002). and Clonidine Help Children With ADHD and Tics". 27. ^{{cite web | title=Clonidine Oral Uses |url=http://www.webmd.com/drugs/mono-24-CLONIDINE+-+ORAL.aspx?drugid=11754&drugname=Clonidine&source=0|publisher=Web MD}} 28. ^{{cite web|title=EPAR summary for the public: Dexdomitor|url=http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/veterinary/000070/WC500062498.pdf|website=www.ema.europa.eu/ema/|publisher=European Medicines Agency|accessdate=July 22, 2017}} 29. ^{{Cite web |url=http://www.online-medical-dictionary.org/Idazoxan.asp?q=Idazoxan |title=online-medical-dictionary.org |access-date=2007-12-26 |archive-url=https://web.archive.org/web/20070824133343/http://www.online-medical-dictionary.org/Idazoxan.asp?q=Idazoxan |archive-date=2007-08-24 |dead-url=yes |df= }} External links
2 : Adrenergic receptors|Human proteins |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 随便看 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。